XNAS · Healthcare · Biotechnology
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.02 | -0.04 | -100.00% | $34.7M | ❌ Miss | +4.96% | -10.04% | — |
| 2026-02-26 | Q4 2025 | -0.03 | -0.02 | +33.33% | $40.6M | ✅ Beat | +0.00% | -15.00% | -34.69% |
| 2025-11-04 |
| Q3 2025 |
| -0.02 |
| -0.04 |
| -100.00% |
| $38.2M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -0.01 | -0.02 | -100.00% | $37.2M | ❌ Miss | +2.72% | +0.76% | -1.52% |
| 2025-02-27 | Q4 2024 | -0.03 | 0.02 | +166.67% | $40.8M | ✅ Beat | +20.49% | +15.12% | +7.32% |
| 2024-08-06 | Q2 2024 | -0.04 | -0.06 | -50.00% | $36.0M | ❌ Miss | -25.09% | -23.60% | -32.58% |
| 2024-05-07 | Q1 2024 | -0.09 | -0.02 | +77.78% | $34.7M | ✅ Beat | +4.88% | -2.09% | +26.48% |
| 2024-03-12 | Q4 2023 | -0.16 | -0.07 | +56.25% | $34.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.